216 related articles for article (PubMed ID: 35366939)
1. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
[TBL] [Abstract][Full Text] [Related]
2. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.
John J; Woolaver RA; Popolizio V; Chen SMY; Ge H; Krinsky AL; Vashisht M; Kramer Y; Chen Z; Wang JH
Front Immunol; 2022; 13():992630. PubMed ID: 36330507
[TBL] [Abstract][Full Text] [Related]
3. Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders.
John J; Chen SMY; Woolaver RA; Ge H; Vashisht M; Huang Z; Chen Z; Wang JH
Front Immunol; 2023; 14():1100520. PubMed ID: 37051229
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
Front Immunol; 2022; 13():794251. PubMed ID: 35355980
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites.
Muijlwijk T; Nijenhuis DNLM; Ganzevles SH; Brink A; Ke C; Fass JN; Rajamanickam V; Leemans CR; Koguchi Y; Fox BA; Poell JB; Brakenhoff RH; van de Ven R
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212122
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model.
Pezeshki A; Cheville JC; Florio AB; Leibovich BC; Vasmatzis G
Front Immunol; 2024; 15():1356144. PubMed ID: 38605943
[TBL] [Abstract][Full Text] [Related]
7. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC; Dillon MT; Nenclares P; Grove L; Soliman H; Leslie I; Northcote D; Bozhanova G; Crespo-Rodriguez E; Baldock H; Whittock H; Baker G; Kyula J; Guevara J; Melcher AA; Harper J; Ghadially H; Smith S; Pedersen M; McLaughlin M; Harrington KJ
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314434
[TBL] [Abstract][Full Text] [Related]
8.
Shi Y; Ren X; Cao S; Chen X; Yuan B; Brasil da Costa FH; Rodriguez Rosario AE; Corona A; Michikawa C; Veeramachaneni R; Osman AA; Xie T; Wang W; Sikora AG; Myers JN; Rangel R
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604640
[TBL] [Abstract][Full Text] [Related]
9. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
[No Abstract] [Full Text] [Related]
10. Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Yoo SH; Yun J; Keam B; Hong SP; Ock CY; Koh J; Kim S; Jeon YK; Jung KC; Kim M; Kim TM; Kim DW; Kim JI; Heo DS
Cancer Immunol Immunother; 2021 Jun; 70(6):1755-1769. PubMed ID: 33389015
[TBL] [Abstract][Full Text] [Related]
11. Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.
Gil-Jimenez A; van Dijk N; Vos JL; Lubeck Y; van Montfoort ML; Peters D; Hooijberg E; Broeks A; Zuur CL; van Rhijn BWG; Vis DJ; van der Heijden MS; Wessels LFA
Nat Commun; 2024 Mar; 15(1):2538. PubMed ID: 38514623
[TBL] [Abstract][Full Text] [Related]
12. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract][Full Text] [Related]
13. Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy.
Lee YM; Hsu CL; Chen YH; Ou DL; Hsu C; Tan CT
Cancer Immunol Res; 2023 Nov; 11(11):1553-1567. PubMed ID: 37669022
[TBL] [Abstract][Full Text] [Related]
14. A Macrophages-Enriched Head and Neck Tumor Spheroid Model to Study Foslip
Francois A; Dirheimer L; Chateau A; Lassalle HP; Yakavets I; Bezdetnaya L
Int J Nanomedicine; 2023; 18():6545-6562. PubMed ID: 37965282
[TBL] [Abstract][Full Text] [Related]
15. Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma.
Bao J; Betzler AC; Hess J; Brunner C
Front Immunol; 2023; 14():1233085. PubMed ID: 37868967
[TBL] [Abstract][Full Text] [Related]
16. Head and neck cancer treatment in the era of molecular medicine.
Pandruvada S; Kessler R; Thai A
Adv Cancer Res; 2023; 160():205-252. PubMed ID: 37704289
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Mukherjee D; Romano E; Walshaw R; Zeef LAH; Banyard A; Kitcatt SJ; Cheadle EJ; Tuomela K; Pendharkar S; Al-Deka A; Salerno B; Raby S; Mills IG; Honeychurch J; Illidge TM
Oncoimmunology; 2023; 12(1):2223094. PubMed ID: 37332616
[TBL] [Abstract][Full Text] [Related]
18. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Oliveira G; Egloff AM; Afeyan AB; Wolff JO; Zeng Z; Chernock RD; Zhou L; Messier C; Lizotte P; Pfaff KL; Stromhaug K; Penter L; Haddad RI; Hanna GJ; Schoenfeld JD; Goguen LA; Annino DJ; Jo V; Oppelt P; Pipkorn P; Jackson R; Puram SV; Paniello RC; Rich JT; Webb J; Zevallos JP; Mansour M; Fu J; Dunn GP; Rodig SJ; Ley J; Morris LGT; Dunn L; Paweletz CP; Kallogjeri D; Piccirillo JF; Adkins DR; Wu CJ; Uppaluri R
Sci Immunol; 2023 Sep; 8(87):eadf4968. PubMed ID: 37683037
[TBL] [Abstract][Full Text] [Related]
19. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.
Bai X; Attrill GH; Gide TN; Ferguson PM; Nahar KJ; Shang P; Vergara IA; Palendira U; da Silva IP; Carlino MS; Menzies AM; Long GV; Scolyer RA; Wilmott JS; Quek C
Nat Commun; 2024 Apr; 15(1):3014. PubMed ID: 38589406
[TBL] [Abstract][Full Text] [Related]
20. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham M; Lucas PC; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
bioRxiv; 2023 Aug; ():. PubMed ID: 37662409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
